ERRATUM|
September 22, 2020
Martinez-Lopez J, Wong SW, Shah N, et al. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Blood Adv. 2020;4(14):3295-3301.
Blood Adv (2020) 4 (18): 4573.
Article history
Submitted:
August 21, 2020
Accepted:
August 21, 2020
Connected Content
Citation
Martinez-Lopez J, Wong SW, Shah N, et al. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Blood Adv. 2020;4(14):3295-3301.. Blood Adv 2020; 4 (18): 4573. doi: https://doi.org/10.1182/bloodadvances.2020003234
Download citation file: